Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
CMPI was delisted on the 27th of May, 2022.
37 hedge funds and large institutions have $202M invested in Checkmate Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 1 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
3% more funds holding
Funds holding: 36 → 37 (+1)
14% less capital invested
Capital invested by funds: $236M → $202M (-$33.4M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.52M |
| 2 |
BlackRock
New York
|
+$1.74M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.02M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$947K |
| 5 |
CT
Cambridge Trust
Cambridge,
Massachusetts
|
+$350K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$932K |
| 2 |
Millennium Management
New York
|
-$886K |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$100K |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$71.1K |
| 5 |
Morgan Stanley
New York
|
-$48.7K |
CMPI Hedge Fund Activity: Q1 2021 in Review
37 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) for Q1 2021, worth a combined $202M — down 14% from $236M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CMPI positions and 1 closed out — a net gain of 1 holder — while 17 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.52M. The largest seller was Deutsche Bank, cutting an estimated $932K.
- 37 institutional investors held Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) as of Q1 2021, up from 36 in Q4 2020.
- Funds reported $202M of Checkmate Pharmaceuticals, Inc. Common Stock stock for Q1 2021, down 14% quarter-over-quarter.
- 2 funds opened new Checkmate Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 1 closed out, a net change of +1 holder.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $3.52M added.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was Deutsche Bank, an estimated $932K sold.
Based on aggregated 13F filings for Q1 2021.